Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis.

ABSTRACT:

Background

The effect of immunomodulatory therapy with tocilizumab for coronavirus disease 2019 (COVID-19) in real-life clinical practice remains controversial.

Methods

Single-center retrospective matched cohort analysis including 47 consecutive patients treated with intravenous tocilizumab for severe COVID-19 pneumonia ("TCZ group"), matched by age, comorbidities, time from symptoms onset and baseline SpO₂/FiO₂ ratio with 47 patients receiving standard of care alone ("SoC group").

Results

There were no significant differences between the TCZ and SoC groups in the rate of clinical improvement (hospital discharge and/or a decrease of ≥2 points on a six-point ordinal scale) by day 7 (51.1% [24/47] versus 48.9% [23/47]; P-value = 1.000). No d

SUBMITTER: Fernandez-Ruiz M 

PROVIDER: S-EPMC9219095 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature